[go: up one dir, main page]

SI1092429T1 - Pharmaceutical preparations for drugs of low solubility - Google Patents

Pharmaceutical preparations for drugs of low solubility

Info

Publication number
SI1092429T1
SI1092429T1 SI9430465T SI9430465T SI1092429T1 SI 1092429 T1 SI1092429 T1 SI 1092429T1 SI 9430465 T SI9430465 T SI 9430465T SI 9430465 T SI9430465 T SI 9430465T SI 1092429 T1 SI1092429 T1 SI 1092429T1
Authority
SI
Slovenia
Prior art keywords
active agent
component
drugs
iii
pharmaceutical preparations
Prior art date
Application number
SI9430465T
Other languages
Slovenian (sl)
Inventor
Ulrich Posanski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6492300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1092429(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI1092429T1 publication Critical patent/SI1092429T1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Pharmaceutical prepn. comprises () a pharmaceutically active agent which is sparingly soluble in water; and (b) a carrier compsn. comprising (i) at least one polyglycerine fatty acid ester and/or at least one sorbitan fatty acid ester, (ii) at least 1 conventional pharmaceutical oil contg. a triglyceride as lipophilic component and (iii) at least 1 nonionic surfactant with a HLB value of at least 10. The active agent is pref. a cyclosporin, rapamycin, tacrolimus, deoxyspergualine, nifedipine, nimodipine, etoposide, ibuprofen or alpha-lipoic acid. The active agent has a solubility, in distilled water, of less than 500mg/1000ml. The active agent concn. is 1-30 wt.%, based on the carrier compsn. The carrier compsn. comprises 10-50 wt.% component (i), 5-40 wt% component (ii) and 10-50 wt % component (iii).
SI9430465T 1993-07-08 1994-07-08 Pharmaceutical preparations for drugs of low solubility SI1092429T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4322826A DE4322826A1 (en) 1993-07-08 1993-07-08 Pharmaceutical preparation
EP00122248A EP1092429B1 (en) 1993-07-08 1994-07-08 Pharmaceutical preparations for drugs of low solubility

Publications (1)

Publication Number Publication Date
SI1092429T1 true SI1092429T1 (en) 2004-08-31

Family

ID=6492300

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9430465T SI1092429T1 (en) 1993-07-08 1994-07-08 Pharmaceutical preparations for drugs of low solubility

Country Status (24)

Country Link
EP (3) EP0710104B1 (en)
JP (4) JPH08512303A (en)
KR (2) KR100386533B1 (en)
CN (2) CN1121853C (en)
AT (3) ATE172876T1 (en)
AU (2) AU7385094A (en)
BR (1) BR9407002A (en)
CA (2) CA2166204C (en)
CY (2) CY2308B1 (en)
CZ (1) CZ291401B6 (en)
DE (6) DE4322826A1 (en)
DK (3) DK0710104T3 (en)
ES (3) ES2218046T3 (en)
FI (2) FI116197B (en)
GR (1) GR3036571T3 (en)
HU (2) HU223073B1 (en)
NO (2) NO306763B1 (en)
NZ (2) NZ269808A (en)
PL (1) PL179717B1 (en)
PT (2) PT1092429E (en)
RU (1) RU2140291C1 (en)
SI (1) SI1092429T1 (en)
SK (1) SK280615B6 (en)
WO (2) WO1995001786A1 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (en) 1993-05-27 1996-06-28 Sandoz Ag Pharmaceutical formulations.
DE4322826A1 (en) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmaceutical preparation
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US6696413B2 (en) * 1995-06-16 2004-02-24 Hexal Ag Pharmaceutical preparation with cyclosporin A
BE1009856A5 (en) 1995-07-14 1997-10-07 Sandoz Sa Pharmaceutical composition in the form of a solid release including macrolide and a vehicle.
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
GB2317562B (en) * 1995-07-20 1999-08-18 Danbiosyst Uk Lipid vehicle drug delivery composition containing vitamin E
US5597582A (en) * 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides
DE19544507B4 (en) * 1995-11-29 2007-11-15 Novartis Ag Cyclosporin containing preparations
CZ288631B6 (en) * 1996-01-18 2001-08-15 Galena, A. S. Therapeutic preparations containing cyclosporin
CZ288739B6 (en) * 1996-08-01 2001-08-15 Galena, A. S. Cyclosporin containing medicinal preparations
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9705813D0 (en) * 1997-03-20 1997-05-07 Smithkline Beecham Plc Novel compositions
JP4221762B2 (en) * 1997-04-11 2009-02-12 アステラス製薬株式会社 Pharmaceutical composition
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
ID25908A (en) * 1998-03-06 2000-11-09 Novartis Ag EMULSION PRACTONCENTRATES CONTAINING CYCLOSPORINE OR MACROLIDES
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB2344520A (en) * 1998-12-08 2000-06-14 Phares Pharm Res Nv Pharmaceutical carriers comprising lipids and polymers
JP2002534370A (en) 1998-12-30 2002-10-15 デクセル リミテッド Dispersible concentrate for delivering cyclosporin
AU2878801A (en) * 1999-10-01 2001-05-10 Natco Pharma Limited An improved pharmaceutical composition and a process for its preparation
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
JP4388743B2 (en) * 2000-11-24 2009-12-24 第一三共ヘルスケア株式会社 Water-soluble oral solution
DE10161077A1 (en) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Highly concentrated stable meloxicam solutions for needleless injection
BR0117197A (en) 2001-12-14 2004-12-14 Jagotec Ag Drug formulation containing cyclosporine application of same
RU2217170C2 (en) * 2002-02-08 2003-11-27 Мельников Глеб Евгеньевич Disinfecting agent
RU2217169C2 (en) * 2002-02-08 2003-11-27 Мельников Глеб Евгеньевич Disinfecting agent
KR100533458B1 (en) 2002-07-20 2005-12-07 대화제약 주식회사 Composition for solubilization of paclitaxel and preparation method thereof
GB2391473B (en) * 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
FR2850275B1 (en) * 2003-01-24 2005-04-08 Scherer Technologies Inc R P SOFT MACHINE CAPSULES CONTAINING AN ACTIVE ACTIVE SUBSTANCE WITH MASK TASTE
WO2004069247A1 (en) 2003-02-06 2004-08-19 Cipla Ltd Topical immunotherapy and compositions for use therein
WO2004073692A1 (en) * 2003-02-18 2004-09-02 Yamashita, Shinji Hard capsule of hardly water-soluble drug
EP1653931A2 (en) * 2003-07-17 2006-05-10 Banner Pharmacaps, Inc. Controlled release preparations
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
GB0425255D0 (en) * 2004-11-16 2004-12-15 Novartis Ag Pharmaceutical composition
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
CA2616806A1 (en) * 2005-07-28 2007-02-08 Reliant Pharmaceuticals, Inc. Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
EP2117521B1 (en) 2006-11-03 2012-06-27 Durect Corporation Transdermal delivery systems comprising bupivacaine
EP1952807A1 (en) 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
ITMI20070720A1 (en) * 2007-04-06 2008-10-07 Monteresearch Srl ORAL COMPOSITIONS CONTAINING TACROLIMUS IN AMORPHOUS FORM
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2416792A4 (en) * 2009-04-10 2012-10-24 Haiyan Qi NEW ANTI-AGING APPROACHES AND METHOD FOR IDENTIFYING THEM
EP2488145B1 (en) 2009-10-12 2024-04-24 Boehringer Ingelheim Vetmedica GmbH Containers for compositions comprising meloxicam
SG183846A1 (en) 2010-03-03 2012-10-30 Boehringer Ingelheim Vetmed Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP5970224B2 (en) 2011-07-11 2016-08-17 株式会社日本自動車部品総合研究所 Spark plug for internal combustion engine
KR20140071913A (en) * 2012-12-04 2014-06-12 삼성정밀화학 주식회사 Food composition and soft capsule including the same
JP6433085B2 (en) * 2013-04-09 2018-12-05 ボストン バイオメディカル, インコーポレイテッド 2-acetylnaphtho [2,3-b] furan-4,9-dione for use in the treatment of cancer
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
DK3215127T3 (en) * 2014-11-07 2021-02-01 Sublimity Therapeutics Ltd COMPOSITIONS INCLUDING CYCLOSPORIN
CN105828827A (en) 2014-11-21 2016-08-03 杭州领业医药科技有限公司 Solid preparation comprising tofogliflozin and method for producing same
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
EP3925610A1 (en) 2016-04-20 2021-12-22 VeroScience LLC Composition and method for treating metabolic disorders
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
HRP20241365T1 (en) * 2017-10-18 2024-12-20 Veroscience Llc IMPROVED BROMOCRIPTINE FORMULATIONS
EA202092131A1 (en) * 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед NEW PHARMACEUTICAL PREPARATION CONTAINING DUAL ANTAGONISTS OF THE NK-1 / NK-3 RECEPTOR
CN108853044B (en) * 2018-07-06 2020-11-06 郑州明泽医药科技有限公司 Nifedipine sustained release tablet and preparation method thereof
AU2019308326B2 (en) 2018-07-20 2025-07-31 Lipocine Inc. Liver disease
US11607455B2 (en) 2019-09-23 2023-03-21 Veroscience Llc Method for inducing tumor regression
KR20220140711A (en) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 Reduced Impurity Sustained Release Drug Delivery Systems and Related Methods
KR102583074B1 (en) * 2021-01-25 2023-09-25 윤관식 Water-soluble emulsion composition comprising natural polyphenolic compound
KR102712501B1 (en) * 2021-02-26 2024-10-02 윤관식 Water-soluble emulsion composition comprising alkaloids
WO2022131656A1 (en) * 2020-12-15 2022-06-23 윤관식 Alkaloid-containing, water-soluble emulsified composition
KR102524312B1 (en) * 2020-12-15 2023-04-21 윤관식 Water-soluble emulsion composition comprising ecdysteroid
KR20230145053A (en) 2021-01-12 2023-10-17 듀렉트 코퍼레이션 Sustained-release drug delivery systems and related methods
CN113041236B (en) * 2021-03-23 2023-03-10 广州新济药业科技有限公司 Flurbiprofen cataplasm and preparation method thereof
KR20240173178A (en) * 2023-06-02 2024-12-10 주식회사 지엔티파마 Pharmaceutical composition containing crisdesalazine with improved stability and dissolution rate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1132518A (en) * 1965-02-18 1968-11-06 Richardson Merrell Inc Medicinal composition
IT1090703B (en) * 1976-12-03 1985-06-26 Scherer Ltd R P IMPROVEMENT IN USEFUL COMPOSITIONS SUCH AS DRUG VEHICLES
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
AU609242B2 (en) * 1988-01-29 1991-04-26 Novartis Ag Cyclosporin compositions
KR0148748B1 (en) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 Pharmaceutical composition containing cyclosporin
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
CA2038744C (en) * 1990-03-23 2002-01-08 Yoshitomi Pharmaceutical Industries Ltd. Pharmaceutical composition containing slightly water-soluble drug
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
JPH0525037A (en) * 1991-07-01 1993-02-02 Upjohn Co:The Oral administrative enzyme sensitive enteric coating
RU2053764C1 (en) * 1991-07-19 1996-02-10 Эгиш Дьедьсердьяр Soft gelatin capsule and method for its production
DE4322826A1 (en) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmaceutical preparation

Also Published As

Publication number Publication date
SK280615B6 (en) 2000-05-16
EP0710104A1 (en) 1996-05-08
CA2164100A1 (en) 1995-01-19
NO960069L (en) 1996-01-05
FI960042A0 (en) 1996-01-04
JP2011153150A (en) 2011-08-11
FI116197B (en) 2005-10-14
CZ291401B6 (en) 2003-03-12
FI960042L (en) 1996-01-04
CZ4596A3 (en) 1996-04-17
PT1092429E (en) 2004-08-31
JPH08512301A (en) 1996-12-24
ES2159564T3 (en) 2001-10-16
HU9503965D0 (en) 1996-03-28
HU9503868D0 (en) 1996-02-28
RU2140291C1 (en) 1999-10-27
AU689486B2 (en) 1998-04-02
PL179717B1 (en) 2000-10-31
DE4494850D2 (en) 1996-08-22
CN1496743A (en) 2004-05-19
SK1996A3 (en) 1997-04-09
DE59407239D1 (en) 1998-12-10
DE59409787D1 (en) 2001-07-19
BR9407002A (en) 1996-09-03
KR100359044B1 (en) 2003-02-05
PL312255A1 (en) 1996-04-01
NO960062L (en) 1996-01-05
ATE172876T1 (en) 1998-11-15
CN1313154C (en) 2007-05-02
GR3036571T3 (en) 2001-12-31
EP0710104B1 (en) 1998-11-04
FI960032A0 (en) 1996-01-03
JPH08512303A (en) 1996-12-24
ES2124420T3 (en) 1999-02-01
DK1092429T3 (en) 2004-07-19
DE4494851D2 (en) 1996-12-19
NO960069D0 (en) 1996-01-05
PT710103E (en) 2001-11-30
HUT73427A (en) 1996-07-29
DE4322826A1 (en) 1995-01-12
EP0710103A1 (en) 1996-05-08
CY2308B1 (en) 2003-11-14
CN1121853C (en) 2003-09-24
ATE261720T1 (en) 2004-04-15
AU7345794A (en) 1995-02-06
DE59410365D1 (en) 2004-04-22
ES2218046T3 (en) 2004-11-16
CA2166204C (en) 2009-04-14
HU223073B1 (en) 2004-03-01
HU228127B1 (en) 2012-12-28
NZ269552A (en) 1996-07-26
CA2166204A1 (en) 1995-01-19
EP0710103B1 (en) 2001-06-13
NZ269808A (en) 1996-07-26
NO306763B1 (en) 1999-12-20
FI116714B (en) 2006-02-15
WO1995001786A1 (en) 1995-01-19
JP2009138008A (en) 2009-06-25
WO1995001785A1 (en) 1995-01-19
CN1128495A (en) 1996-08-07
ATE201985T1 (en) 2001-06-15
KR100386533B1 (en) 2003-08-21
AU7385094A (en) 1995-02-06
DK0710104T3 (en) 1999-07-19
EP1092429A1 (en) 2001-04-18
EP1092429B1 (en) 2004-03-17
CY2604B2 (en) 2010-04-28
HUT73661A (en) 1996-09-30
FI960032L (en) 1996-02-09
NO960062D0 (en) 1996-01-05
DK0710103T3 (en) 2001-09-24
NO306929B1 (en) 2000-01-17

Similar Documents

Publication Publication Date Title
SI1092429T1 (en) Pharmaceutical preparations for drugs of low solubility
PT787011E (en) PRE-CONCENTRATE OF MICROEMULSION UNDERSTANDING A MACROLID